Psomagen Inc.

CLIA & CAP, US-based contract services lab making multiomics tools and technologies accessible and s Biotechnology company in Rockville, Maryland
Psomagen, Inc.

(previously Macrogen Corp.), established in 2004, offers “total genomic solutions” for both clinical and research purposes, mainly focusing on end-to-end sequencing services. The company will expand its services to include personal DNA tests.

01/28/2026

We love hearing from satisfied customers — and there’s something extra-special about partners who’ve been with us since the beginning! Psomagen Sanger customers have access to:

⏰16-24 hour turnaround time on standard orders.

💰 Competitive pricing, with special deals for bulk orders, referrals, and pre-labeled samples.

✔️ High-quality results, with expert in-house support from sample QC to data analysis.

We’re proud to support researchers at every stage, whether you’ve been with us for years or are just getting started. Ready to move your next project forward? Visit our website to see how Psomagen Sanger sequencing can work for you: https://hubs.ly/Q0404xpJ0

01/26/2026

Shotgun metagenomic sequencing provides a view of a whole microbial community's genetic makeup. This includes bacteria archaea, fungi, and viruses. With this next-gen technology you gain access to unbiased community discovery and high-resolution taxa identification capabilities.

You can try out the technology for a discount! New shotgun metagenomics customers can get their first order 50% off with code METAFIRST50%. This applies to orders of 50+ samples — visit our promos page to learn more: https://hubs.ly/Q03_7BBp0

01/20/2026

CAR-T treatments for autoimmune diseases like Myasthenia Gravis are just now coming into the clinical space. In this Phase 2b clinical trial of the RNA drug, Decartes-08, scientists achieved their primary endpoint with 66.7% of patients who received the drug showing responses up to 12 months post-infusions.

Descartes-08 is an autologous CAR-T therapy utilizing an RNA-encoded anti-B cell maturation antigen (BCMA). BCMA is a surface antigen on plasma cells and plasmacytoid dendritic cells that is rarely found on B-cells, thus it poses less risk of adverse events than with traditional CAR-T therapies.

Multiple approaches were utilized to monitor the immune status, including the Olink Target 96 Inflammation panel run in Psomagen’s labs. Check out this exciting work in Nature Medicine to view the data on this novel new treatment for autoimmune diseases: https://go.nature.com/4qWUv4T

01/15/2026

Our labs have achieved Olink Certified Service Provider status for the new Olink Reveal platform — making us a trusted CSP for all Olink services. Reveal is a more affordable option for discovery-level proteomics. With over 1,000 targets and 96% coverage of the top 29 Reactome pathways, immune-related breakthroughs are imminent!

Visit our website to learn more: https://bit.ly/3YDxdVV

01/13/2026

Take a look at the latest from Psomagen customers in this recent study! Pulmonary Mycobacterium tuberculosis infection causes a wide variety of lesions. However, we don’t know much about the mechanisms regulating the development of the different lesions. In this study, scientists used a mouse model to demonstrate that neutrophils and CD4 T cells are involved in a counter-regulation process that informs pulmonary Mtb pathology. These interactions occur early in infection onset and determine the disease pathology.

Psomagen provided single-cell sequencing using a 10x Genomics workflow on the Illumina NovaSeq X Plus. These results provide insight that could be applied to tuberculosis prevention and treatment plans. Read the full study here: https://bit.ly/3Z3BmCr

01/05/2026

In the NCT05447702 clinical trial for stage II/III TNBC, researchers demonstrated clinical efficacy of camrelizumab and apatinib combined with chemotherapy. Using Olink serum proteomics, these clinicians also uncovered a predictive stratification scoring system and an efficacy evaluation assessment system. Read the full study here: https://go.nature.com/4q0gacr

Don’t miss out on what Olink proteomics can add to your research. Get in touch with our Olink Certified Service Provider lab today!

12/18/2025

Using publicly available scRNA sequencing data and conducting spatial transcriptional profiling with the 10x Genomics Visium, researchers created an atlas of human skin fibroblasts in healthy and numerous disease states. Based on their findings, scientists have proposed a formal nomenclature for skin fibroblasts based on their spatial locations and gene expression profiles. The annotated database of skin fibroblasts in healthy and disease states is a fantastic resource for those studying human skin. You can read the project summary and get details on data availability here: https://go.nature.com/4oYxPzO

12/16/2025

Psomagen is proud to have provided Olink Proteomics runs for this recent oncology research out of the Children's Hospital of Philadelphia. In this study, researchers hypothesized that patients with acute myeloid leukemia (AML) could respond to CAR-T directed against myeloid targets based on the excellent responses of patients with acute lymphoblastic leukemia (B-ALL) to CAR-T directed against CD19 or CD22. All treatments with CAR-T involve a risk of the adverse immune-related event called cytokine release syndrome (CRS), and this study limited analysis to patients demonstrating only mild cases of CRS.

The Olink immunoassay platform was used to compare circulating protein levels in an AML CAR-T clinical trial to two B-ALL CAR-T clinical trials. The unique protein signatures identified here have the potential to decrease the risk of CRS and improve treatment response to CAR-T therapies.

Read the full study here: https://bit.ly/4rXRbrG

12/08/2025

As technology advances, we've learned that RNA expression doesn't guarantee matching protein expression. Factors like the cell state or environment, regulatory mechanisms, molecule stability, and translation rate can be partly to blame for these differences — but that's just the start of the list!

In this recent article, take a look at more causes of RNA and protein expression discrepancies, as well as our traditional limitations in detecting or understanding these differences. Then, see an explanation and case studies of spatial biology technology used to analyze RNA and protein expression. This technology is leading to clearer, more confident insights in multiomics studies.

Get the full blog here: https://bit.ly/3XGQfdh

12/04/2025

10x Genomics Flex v2 has all of the original platform's multiplexing benefits, at a significantly lower cost. This is a great opportunity for anyone looking to jump into single-cell for the first time, or increase the size of their experiment without breaking the bank. Flex v2 offers:
1. Multiplexing for up to 384 samples, eliminating batch effects.
2. Fixation options for samples collected at different timepoints.
3. Compatibility with frozen tissue, cryopreserved cells, FFPE tissue, or nuclei.
4. Probe-based whole transcriptome analysis, covering over 18,000 genes.

Learn more about starting your next 10x Genomics single-cell project: https://bit.ly/44nqWAE

12/02/2025

The latest in protein news: scientists studying multiple sclerosis identified potential circulating biomarkers of disease activity using the Olink Proteomics Target 96 Inflammation assay. Results of the study indicate that neuroinflammatory factors of MS are present in radiologically isolated syndrome (RIS). Read the full study here: https://bit.ly/4rqAhSs

Want to advance your research with Olink proteomics? Psomagen is a Certified Service Provider across the entire Olink portfolio. Contact us today!

11/25/2025

New in oncology research: researchers used the CosMx Spatial Molecular Imager (SMI) to analyze the composition of cells at the invasive margin of colorectal tumors. Cancer cell clusters with budding cells were closely located with cancer associated fibroblasts (CAFs) and demonstrated stark transcriptional changes related to epithelial-mesenchymal transition, extracellular matrix, and migration. These findings suggest that CAFs are stimulating the transcriptional changes for pro-invasion.

Read the article here: https://hubs.ly/Q03P8KYs0

Address

1330 Piccard Drive
Rockville, MD
20850

Telephone

+13012511007

Website

https://psomagen.com/

Alerts

Be the first to know and let us send you an email when Psomagen Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Psomagen Inc.:

Shortcuts

Want your practice to be the top-listed Clinic in Rockville?